Cognoa

Cognoa is a pediatric behavioral health company focused on developing AI-based technologies for early diagnosis and care of children with developmental and behavioral health conditions, with a primary focus on autism spectrum disorder (ASD). The company's main product is Canvas Dx, the first FDA-authorized diagnostic device for autism in children aged 18 to 72 months. Canvas Dx uses AI to analyze inputs from parents and healthcare providers, including questionnaires and videos of the child, to aid in diagnosing or ruling out autism. 

In addition to Canvas Dx, Cognoa's product pipeline includes diagnostic and therapeutic tools for other conditions such as speech and language disorders, ADHD, and childhood anxiety. 

Key customers and partnerships

In February 2023, Cognoa partnered with the Health Transformation Alliance (HTA), a cooperative of nearly 60 of America's largest employers, to offer Canvas Dx to HTA member organizations and their employees. Further in January 2024, Highmark became Cognoa's first commercial payer partner, agreeing to reimburse Canvas Dx for its commercial members. Cognoa has also participated in early start programs in Wyoming, Arizona, and California, allowing Canvas Dx to be prescribed and reimbursed under each state's Medicaid plan.